1 - ------------------------------------------------------------------------------- - ------------------------------------------------------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 --------------- FORM 8-K CURRENT REPORT, PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JUNE 5, 1998 (JUNE 1, 1998) NU-TECH BIO-MED, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 0-11772 25-1411971 - ---------------------------- ------------------------ ------------------- (State or Other Jurisdiction (Commission File Number) (I.R.S. Employer of Incorporation) Identification No.) 476 MAIN STREET - SUITE 3-DFL WAKEFIELD, RHODE ISLAND 02879 ---------------------------------------- ---------- (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (401) 789-9995 --------------- - ------------------------------------------------------------------------------- - ------------------------------------------------------------------------------- 2 ITEM 5. OTHER EVENTS. On June 1, 1998, the Company was notified by The Nasdaq Stock Market that the Company's Common Stock would be delisted from the Nasdaq SmallCap Market, effective as of the close of business on June 1, 1998. The notification resulted from a determination by a Nasdaq Listing Qualifications Panel, following a hearing held on May 14, 1998, to reject the Company's request for continued inclusion on the SmallCap Market. -2- 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. NU-TECH BIO-MED, INC. By: /s/ J. MARVIN FEIGENBAUM --------------------------------------- Name: J. Marvin Feigenbaum Title: Chairman of the Board, President, Chief Executive and Chief Financial Officer Date: June 5, 1998 -3-